-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, M08pDnLyQrwPfV3LkZuOrknATFuG6r63HKxFOg4F5j0cuSJFVulu6ru1iDdl1KQ0 PG4AmV6bq97gzHve9wtPdQ== 0000933745-06-000003.txt : 20060316 0000933745-06-000003.hdr.sgml : 20060316 20060316140153 ACCESSION NUMBER: 0000933745-06-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060316 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20060316 DATE AS OF CHANGE: 20060316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIRAVANT MEDICAL TECHNOLOGIES CENTRAL INDEX KEY: 0000933745 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770222872 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25544 FILM NUMBER: 06691155 BUSINESS ADDRESS: STREET 1: 336 BOLLAY DRIVE CITY: SANTA BARBARA STATE: CA ZIP: 93117 BUSINESS PHONE: 8056859880 MAIL ADDRESS: STREET 1: 336 BOLLAY DRIVE CITY: SANTA BARBARA STATE: CA ZIP: 93117 FORMER COMPANY: FORMER CONFORMED NAME: PDT INC /DE/ DATE OF NAME CHANGE: 19941214 8-K 1 form8kmarch2006kendle.htm FORM 8-K KENDLE TERMINATION MARCH 9, 2006 Form 8-K Kendle Termination March 9, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

March 16, 2006


MIRAVANT MEDICAL TECHNOLOGIES
(Exact name of registrant as specified in its charter)

DELAWARE
  
0-25544
  
77-0222872
(State or other jurisdiction of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)

7408 Hollister Avenue
Santa Barbara, CA 93117
(Address of principal executive offices, including zip code)

(805) 685-9880
(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





 
Item 8.01 Other Events;
 
Item 2.02 Termination of a Material Definitive Agreement.

Miravant Medical Technologies (“the Company’) received notification that Kendle International Inc. (“Kendle”) has terminated its services under the contract between the Company and Kendle, pursuant to which Kendle was providing clinical and regulatory services for the Company’s confirmatory Phase III placebo controlled clinical trial of Photrex™, a therapy being tested for Age-related Macular Degeneration, (“AMD”) being conducted in Central and Eastern Europe. Enrollment in the phase III confirmatory clinical trial was suspended in February 2006 due to unanticipated delays in the start-up of the trial and substantially slower than forecasted patient enrollment in the European trial venues.

Prior to suspension of the trial and Kendle’s termination of the contract, the Company notified Kendle of concerns about Kendle’s performance under the contract. In its termination notice, Kendle cites failure by the Company to pay certain invoices as a ground for termination. Kendle has notified the Company that it has filed a complaint against the Company in the Court of Common Pleas in Hamilton County, Ohio. Among other things, the complaint seeks payment by the Company of all outstanding invoices in the amount of approximately $2 million, plus interest and late charges. The Company is currently reviewing a copy of the complaint and intends to vigorously defend itself, including possibly pursuing claims relating to Kendle’s performance under the contract.

In addition, the Company continues to re-evaluate its clinical and regulatory strategy for Photrex™ in ophthalmology and consider alternative pathways for Photrex™ due to the rapidly changing competitive landscape for the treatment of AMD, the advent of combination therapy approaches, and the additional financial commitment expected to be required for a continuation of the clinical trial under its present design.

Item 5.02(a) Departure of Directors or Principal Officers

Effective March 13, 2005, Rani Aliahmad has resigned as a member of the Company’s board of directors and the board’s executive committee.








SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   
MIRAVANT MEDICAL TECHNOLOGIES
     
 
By:
/s/ John M. Philpott
  
   
John M. Philpott
Chief Financial Officer

Date: March 16, 2006
 -----END PRIVACY-ENHANCED MESSAGE-----